Letter of Offer for the Rights issue

CIN : L10790RJ1991PLC006353 Date: October 29, 2026 The General Manager – Listing Compliance BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. Scrip Code: 519242 Subject: Proposed Rights Issue of the Fully Paid-up Equity Shares of Fresita Proteins Limited (Formerly known as Sarda Proteins Limited) (“the Company”). Dear Sir/Madam, This is in continuation to our earlier letters dated August 05, 2026, and October 26, 2026, wherein the Company has proposed a Rights Issue of 74,79,917 Equity Shares of face value of Rs. 10/- each of the Company at an issue price of Rs. 120/- per Rights Equity Shares aggregating to Rs. 8975.90 Lakhs on rights basis to the eligible shareholders of the Company in the ratio of 5 (Five) Rights Equity Shares for Every 6 (Six) Fully Paid-Up Equity Shares Held on The Record Date. i.e Friday, October 30,2026. In this regard, please find enclosed the soft copy of Letter of Offer dated October 29,2026 for the Rights Issue of Fresita Proteins Limited (Formerly known as Sarda Proteins Limited). Kindly take the note of the above. For & on behalf of the Board of Directors of FRESITA PROTEINS LIMITED (Formerly known as sarda proteins limited) Digital Signer:SAVALIYA SHIRISH DHIRAJBHAI DN:CN=SAVALIYA SHIRISH DHIRAJBHAI, SAVALIYA E P= hoC nH eI =RAG.SAVALIYA31@GMAIL.COM, 4580e5fb78bc67661a652aaabff95c16dedcafaef6987c8bc88 SHIRISH e Ob ID7c .20 .2 5f .1 46 .6e 5fc =f 0, 44e7d952399414eaef180a8c680d537, DHIRAJBHAI 8 a6 3 , d O8 =e P6 efa rs7 o7 n4 ae l3 , b L1 =0 J3 Aa M7 N52 A0 G6 Ac R4b , c3a92bb42 STREET="JAMNAGAR,361160", S=GUJARAT, PostalCode=361160, C=IN Date:29-Oct-26 18:26:49 +05:30 SHIRISH DHIRAJLAL SAVALIYA Managing Director DIN: 08721554 FRESITA PROTEINS LIMITED (Formerly Known as Sarda Proteins Limited) +91 63581 28991 Reg. Office : 2nd Floor, 2, Sai Collection Building, Bus Stand Road, Police Control Room, sardaproteins@yahoo.com | www.fresita.in Alwar Bus Stand Area, Alwar, Rajasthan – 301001 Corporate Office: P-212 B, Gate No. 2, Lodhika GIDC, Rajkot, Metoda, Gujarat, India – 360021 [Please scan this QR Code to view this Letter of Letter of Offer Offer] Dated: October 29,2026 For Eligible Equity Shareholders only FRESITA PROTEINS LIMITED (Formerly known As Sarda Proteins Limited) Fresita Proteins Limited (Formerly known as Sarda Proteins Limited) (hereinafter referred to as “SPL”), was originally incorporated as Public limited Company in the name of Sarda Proteins Limited on December 03, 1991 under the Companies Act, within the jurisdiction of Registrar of Companies, Rajasthan, Jaipur. The name of the company was later changed to “Sarda Proteins Limited" vide fresh certificate of incorporation dated 18th March 1992 issued by the Registrar of Companies, Rajasthan, Jaipur. Thereafter, the name of the company was later changed to “Fresita Proteins Limited" vide fresh certificate of incorporation dated 21st August 2026 issued by the Registrar of Companies, Rajasthan, Jaipur. The Corporate Identity Number of the Company is L10790RJ1991PLC006353. For further details please refer to the section titled “General Information” beginning on page 41 of this Letter of offer. Registered Office: 2nd Floor, 2, Sai Collection Building,BusStand Road, Police Control Room, AlwarBus Stand Area, Alwar, Rajasthan– 301001 Corporate Office: P-212 B, Gate No. 2, Lodhika GIDC, Rajkot, Metoda, Gujarat, India – 360021 Contact person: Ms. Namrata Karwa, Company Secretary & Compliance Officer Contact: +91 6358128991 | E-mail id sardaproteins@yahoo.com| Website: https://www.sardaproteins.in/ Corporate Identity Number: L10790RJ1991PLC006353 PROMOTER OF OUR COMPANY: ONIX RENEWABLE LIMITED FOR PRIVATE CIRCULATION TO THE ELIGIBLE EQUITY SHAREHOLDERS OF FRESITA PROTEINS LIMITED (FORMERLY KNOWN AS SARDA PROTEINS LIMITED) (OUR “COMPANY” OR THE “ISSUER” ONLY) ISSUE OF UP TO 74,79,917 FULLY PAID UP EQUITY SHARES OF FACE VALUE OF ₹10 EACH OF OUR COMPANY (THE “RIGHTS EQUITY SHARES” FOR CASH AT A PRICE OF ₹120/- PER EQUITY SHARE (INCLUDING A PREMIUM OF ₹110 PER EQUITY SHARE) (THE “ISSUE PRICE”) AGGREGATING UP TO ₹8975.90 LAKHS# ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 5 (FIVE) EQUITY SHARE FOR EVERY 6 (SIX) FULLY PAID-UP EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS FRIDAY, OCTOBER 30, 2026 (THE “ISSUE”). THE ISSUE PRICE FOR THE RIGHTS EQUITY SHARES IS 12 TIMES THE VALUE OF THE EQUITY SHARES. FOR FURTHER DETAILS, PLEASE REFER TO “TERMS OF THE ISSUE” BEGINNING ON PAGE 71 #Assuming full subscription. WILFUL DEFAULTERS Neither our Company nor any of our Promoters or any of our directors have been declared as Willful Defaulters or Fraudulent Borrowers by the RBI or any other government authority. GENERAL RISKS Investment in equity and equity related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk with such investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors shall rely on their own examination of our Company and the Issue including the risks involved. The securities being offered in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”) nor does SEBI guarantee the accuracy or adequacy of this Letter of Offer. Specific attention of the investors is invited to "Risk Factors" beginning on page 24. ISSUER'S ABSOLUTE RESPONSIBILITY Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Letter of Offer contains all information with regard to our Company and the Issue, which is material in the context of the Issue, and that the information contained in this Letter of Offer is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which makes this Letter of Offer as a whole or any such information or the expression of any such opinions or intentions misleading in any material respect. LISTING The existing Equity Shares of our Company are listed on BSE Limited and Calcutta Stock Exchange Limited (the “Stock Exchange”). Our Company has received ‘in-principle’ approval from the BSE Limited for listing the Rights Equity Shares to be allotted pursuant to this Issue vide letter dated October 08, 2026. Our Company will also make application to the Bombay Stock Exchange to obtain its trading approval for the Rights Entitlements as required under the SEBI circular bearing reference number SEBI/HO/CFD/DIL2/CIR/P/2020/13 dated January 22, 2020. For the purpose of this Issue, the Designated Stock Exchange is BSE Limited. REGISTRAR TO THE ISSUE MUFG Intime India Private Limited (Formerly known as Link Intime India Private Limited) Address: C-101, Embassy 247, 1st Floor, L B S Marg Vikhroli (West), Mumbai 400 083 Maharashtra, India Telephone: +91 81081 14949 Email: fresitaproteins.rights@in.mpms.mufg.com Website: www.in.mpms.mufg.com Investor grievance E-mail: fresitaproteins.rights@in.mpms.mufg.com Contact Person: Shanti Gopalakrishnan SEBI Registration No.: INR000004058 ISSUE PROGRAMME LAST DATEFOR DATE OF LAST DATEFOR DATE OF DATE OF DATE OF DATE OF DATE OF CREDIT OF OPENING OF ON MARKET CLOSINGOF FINALIZATION ALLOTMENT CREDIT OF LISTING (ON RIGHTS THE ISSUE RENUNCIATION THE ISSUE# OF BASIS OF (ON OR ABOUT) RIGHTS OR ABOUT) ENTITLEMENTS OF RIGHTS ALLOTMENT EQUITY ENTITLEMENTS* (ON OR ABOUT) SHARES (ON OR ABOUT) Monday, Thursday, Friday, Thursday, Friday, Friday, Monday, Monday, November 02, 2026 November 12, 2026 November 20, 2026 November 26, 2026 November 27, 2026 November 27, 2026 November 30, 2026 November 30, 2026 *Eligible Equity Shareholders are requested to ensure that renunciation through off-market transfer is completed in such a manner that th [Showing first 8,000 characters — download PDF for full document]